Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/13/2025 | $13.00 | Outperform | Leerink Partners |
| 8/21/2025 | $18.00 | Overweight | Morgan Stanley |
| 7/1/2025 | $25.00 | Overweight | Cantor Fitzgerald |
| 5/28/2025 | $21.00 | Buy | H.C. Wainwright |
| 3/10/2025 | $9.00 → $29.00 | Outperform → Strong Buy | Raymond James |
| 3/10/2025 | $8.00 → $25.00 | Buy | Needham |
| 12/12/2024 | $6.00 → $7.50 | Buy | H.C. Wainwright |
| 9/9/2024 | $6.00 → $7.00 | Outperform | Leerink Partners |
8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)
SCHEDULE 13G - Trevi Therapeutics, Inc. (0001563880) (Subject)
SCHEDULE 13G - Trevi Therapeutics, Inc. (0001563880) (Subject)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
Leerink Partners initiated coverage of Trevi Therapeutics with a rating of Outperform and set a new price target of $13.00
Morgan Stanley initiated coverage of Trevi Therapeutics with a rating of Overweight and set a new price target of $18.00
Cantor Fitzgerald initiated coverage of Trevi Therapeutics with a rating of Overweight and set a new price target of $25.00
NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, March 17, 2026, at 4:30 p.m. ET, to provide business updates and review the Company's financial results for the fourth quarter and year ended December 31, 2025. Conference Call and WebcastTo register for the live co
NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in March. Leerink Partners 2026 Global Healthcare ConferenceMarch 8 – 11, 2026, Miami, FloridaFireside Chat: March 11, 8:40 a.m. ETTrevi Representatives: Jennifer Good, President and CEO, and James Cassella, Ph.D., CDORegister h
NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, and David Hastings, Chief Financial Officer, will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, at 9:20 a.m. ET. Held virtually from February 25-26, Ms. Good and Mr.
SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
SC 13D/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, March 17, 2026, at 4:30 p.m. ET, to provide business updates and review the Company's financial results for the fourth quarter and year ended December 31, 2025. Conference Call and WebcastTo register for the live co
Company preparing to initiate comprehensive Phase 3 program for chronic cough in patients with idiopathic pulmonary fibrosis in first half of 2026 Company ended the third quarter of 2025 with $194.9 million in cash, cash equivalents and marketable securities with expected cash runway into 2028 Management to host a conference call and webcast today at 4:30 p.m. EST NEW HAVEN, Conn., Nov. 13, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF I
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., Nov. 6, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Thursday, November 13, 2025, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended September 30, 2025.
Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth NEW HAVEN, Conn., Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that David Hastings will assume the role of Chief Financial Officer effective January 6, 2026. www.trevitherapeutics.com (PRNewsfoto/Trevi
WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie
NEW HAVEN, Conn., Sept. 30, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of James V. Cassella, Ph.D., as Chief Development Officer (CDO). www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)" alt="Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)"> "I am delighte